Greenwich LifeSciences (NASDAQ:GLSI) Price Target Raised to $39.00 at HC Wainwright

Greenwich LifeSciences (NASDAQ:GLSI) had its target price hoisted by analysts at HC Wainwright from $38.00 to $39.00 in a note issued to investors on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price suggests a potential upside of 335.75% from the company’s previous close.

Greenwich LifeSciences Trading Up 1.2 %

Shares of GLSI stock opened at $8.95 on Monday. The firm’s 50 day moving average is $10.87 and its 200-day moving average is $12.36. The firm has a market capitalization of $118.80 million, a price-to-earnings ratio of -11.19 and a beta of 1.76. Greenwich LifeSciences has a 1 year low of $8.06 and a 1 year high of $18.75.

Greenwich LifeSciences (NASDAQ:GLSI) last announced its quarterly earnings results on Tuesday, April 15th. The company reported ($0.61) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.40). On average, equities research analysts forecast that Greenwich LifeSciences will post -0.8 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Snehal Patel bought 3,600 shares of the company’s stock in a transaction dated Monday, April 7th. The stock was bought at an average price of $9.10 per share, with a total value of $32,760.00. Following the completion of the acquisition, the chief executive officer now owns 5,561,602 shares of the company’s stock, valued at $50,610,578.20. This represents a 0.06 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 51.67% of the stock is currently owned by corporate insiders.

Institutional Trading of Greenwich LifeSciences

Institutional investors and hedge funds have recently modified their holdings of the business. Garden State Investment Advisory Services LLC bought a new stake in shares of Greenwich LifeSciences in the third quarter worth $253,000. Northern Trust Corp increased its holdings in shares of Greenwich LifeSciences by 17.3% during the fourth quarter. Northern Trust Corp now owns 87,423 shares of the company’s stock valued at $982,000 after acquiring an additional 12,923 shares in the last quarter. Barclays PLC lifted its position in Greenwich LifeSciences by 323.3% in the 3rd quarter. Barclays PLC now owns 8,560 shares of the company’s stock valued at $123,000 after acquiring an additional 6,538 shares in the last quarter. Geode Capital Management LLC increased its stake in Greenwich LifeSciences by 4.6% in the 3rd quarter. Geode Capital Management LLC now owns 133,550 shares of the company’s stock valued at $1,919,000 after buying an additional 5,861 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its position in Greenwich LifeSciences by 172.0% in the fourth quarter. JPMorgan Chase & Co. now owns 7,061 shares of the company’s stock worth $79,000 after acquiring an additional 4,465 shares during the period. 4.16% of the stock is currently owned by institutional investors.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.